|
?:abstract
|
-
Introduction: At the end of March, 2020, rapid tests detecting the presence of antiviral IgM and IgG antibodies against SARS-CoV-2 virus were introduced in Hungary for the identification of SARS-CoV-2 infection (COVID-19 disease) Aim: We evaluated two rapid tests (Anhui and Clungene) in comparison with those of real-time PCR tests considered as the gold standard in the detection of infection Method: Between 16, March and 14, April, 2020, we performed rapid IgM and IgG detecting tests without PCR;PCR without rapid tests;and PCR WITH rapid tests in 4140, 3210 and 1654 patients, respectively (Out of these 1654 patients, Anhui and Clungene tests were used for testing in 625 and 1029 patients, respectively ) Patients were considered as positive in PCR and rapid tests when PCR positivity and IgM or IgG positivity occurred at any time, respectively (Note: Clungene test is also marketed as \'Lungene\' ) Results: The prevalence of PCR positivity in 4864 patients tested with PCR was 6 3% The sensitivity and specificity of Anhui and Clungene tests were 33 3% and 72 85%, and 35 48% and 85 02%, respectively At 6% PCR positivity, the positive and negative predictive values of Anhui and Clungene were 7 28%, 94 48%, 13 13%, and 95 38%, respectively Conclusion: The low positive predictive values indicate that Anhui and Clungene rapid tests detecting the presence of anti-IgM and anti-IgG against SARS-CoV-2 virus infection are not suitable for screening SARS-CoV-2 virus infection in the general population These results strongly support that Anhui and Clungene rapid tests detecting IgM and IgG antibodies against SARS-CoV-2 virus should not be used in the differential diagnosis of infection Orv Hetil 2020;161(20): 807-812
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}